Incannex Healthcare (IXHL) Shares Outstanding (2020 - 2026)
Incannex Healthcare (IXHL) posted quarterly Shares Outstanding (Entity) of $13.7 million for Q1 2026, up 1990.88% year-on-year from $654418.0 in Q1 2025, and up 14.27% on a QoQ basis from $12.0 million in Q4 2025.
Incannex Healthcare (IXHL) Shares Outstanding (2020 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Shares Outstanding (Entity) for 7 consecutive years, with $13.7 million the latest figure, recorded in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 1990.88% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (up 1990.88% YoY) and the FY2025 annual result came in at $1.1 million, up 95.29% from the prior year.
- Shares Outstanding (Entity) grew to $13.7 million in Q1 2026 per IXHL's latest filing, from $12.0 million in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for IXHL reached as high as $13.7 million in Q1 2026 and fell as low as $11667.0 in Q2 2022.
- A 5-year average of $2.9 million and a median of $588094.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) sank 95.36% — and 2023, when it surged 4435.05%.
- Year by year, Shares Outstanding (Entity) stood at $21138.0 in 2022, then soared by 2403.09% to $529104.0 in 2023, then advanced by 12.05% to $592841.0 in 2024, then surged by 1919.76% to $12.0 million in 2025, then grew by 14.27% to $13.7 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $13.7 million, $12.0 million, and $11.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 8.98 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.16 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 422.10 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 43.50 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 455,871.00 |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 100.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 497.70 Mn |
| 10 | Incannex Healthcare | 3.63 Mn | 3.63 Mn | - | 12.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.35 Mn |
| Dec 31, 2025 | 11.65 Mn |
| Sep 30, 2025 | 10.34 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 654,418.00 |
| Dec 31, 2024 | 587,481.00 |
| Sep 30, 2024 | 588,094.00 |
| Jun 30, 2024 | 538,811.00 |
| Mar 31, 2024 | 529,104.00 |
| Dec 31, 2023 | 529,104.00 |
| Sep 30, 2023 | 529,104.00 |
| Jun 30, 2023 | 512,823.00 |
| Mar 31, 2023 | 529,104.00 |
| Dec 31, 2022 | 21,138.00 |
| Jun 30, 2022 | 11,667.00 |
| Jun 30, 2021 | 251,372.00 |
| Jun 30, 2020 | 16,667.00 |